<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02075996</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-10280</org_study_id>
    <nct_id>NCT02075996</nct_id>
  </id_info>
  <brief_title>Non-interventional Study With Pomalidomide (Imnovid®)</brief_title>
  <acronym>Poseidon</acronym>
  <official_title>Non-interventional Study of Pomalidomide (Imnovid®) in Combination With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this non-interventional study is to collect data on the efficiency and safety
      of pomalidomide in combination with dexamethasone in the routine application
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Discontinuation (TTD)</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment (TNT)</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse reaction profile</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>secondary malignancies</measure>
    <time_frame>6 years</time_frame>
    <description>long term safety is focused on secondary malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall Survival (OS)</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative dose intensity of pomalidomide and dexamethasone</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess changes in myeloma-related quality of life</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>explore additional supportive therapies</measure>
    <time_frame>3 years</time_frame>
    <description>To explore additional supportive therapies used on this patient population (e.g. G-CSF, antibiotics, DVT prophylaxis)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">151</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Pomalidomide following lenalidomide</arm_group_label>
    <description>75 patients with pomalidomide directly following lenalidomide treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomalidomide following other therapy</arm_group_label>
    <description>75 patients with pomalidomide following any other prior therapy. This includes lenalidomide in earlier lines than the most recent line.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with relapsing or refractory multiple myeloma previously treated with at
        least two prior lines of therapy, including bortezomib and lenalidomide who have progressed
        under their last therapy regimen
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with relapsed or refractory multiple myeloma Patients must have received at
             least two prior lines of treatment (induction therapy followed by stem cell
             transplantation ± maintenance therapy is considered one prior therapy) and must have
             progressed under the most recent therapy regimen

          -  Adult male and female patients (at least 18 years with no upper age limit)

          -  Written informed consent to data collection and pseudonymized data transfer

          -  The conditions of the Pregnancy Prevention Programme must be fulfilled for all
             patients unless there is reliable evidence that the patient does not have childbearing
             potential (see summary of product characteristics Imnovid®)

          -  Other criteria according to summary of product characteristics Imnovid®

        Exclusion Criteria:

          -  Missing patient's informed consent

          -  Pregnant or breast-feeding women

          -  Male patients, not capable of complying the required preventive measures (see summary
             of product characteristics Imnovid®)

          -  Other criteria according to summary of product characteristics Imnovid®
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Dechow, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>practice based oncology office Ravensburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>iOMEDICO AG</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2014</study_first_submitted>
  <study_first_submitted_qc>February 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pomalidomide, Imnovid, dexamethasone, Poseidon, multiple myeloma, daily routine, secondary malignancies, Germany, non-interventional study, safety,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

